Hansa Medical initiates pivotal multicenter study in the US

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Hansa Medical initiates pivotal multicenter study in the US with IdeS for treatment of refractory highly sensitized kidney patients

Hansa Medical AB (publ) today announced that the company sponsored pivotal multicenter study in the US with IdeS in refractory highly sensitized patients is open for recruitment. The single arm Phase II study will include approximately 20 highly sensitized patients awaiting kidney transplantation, who are refractory to currently available desensitization strategies. The patients in this new study have either failed on previous attempts of desensitization or the currently available methods are considered insufficiently effective. The study is entitled "A Phase II Study to Evaluate the Efficacy of IdeS (IgG endopeptidase) to Desensitize Transplant Patients with a Positive Crossmatch Test" with the short name Highdes. The primary objective of the study is to assess the efficacy of IdeS in creating a negative crossmatch test. The trial will also evaluate safety, kidney function and immunogenicity during the 6-month follow-up period. The aim is to complete recruitment of approximately 20 patients over a 12-month period. The recruitment of patients has been initiated at Cedars-Sinai Medical Center in Los Angeles. "The initial evaluation of the results in the ongoing Phase II studies with IdeS in Sweden and the U.S. verifies our strong belief in the potential of IdeS as a safe, fast and highly effective desensitization treatment. We are excited that we have initiated a fully Hansa Medical sponsored US study with the ambition to recruit patients in immediate need of desensitization”, commented Göran Arvidson, President and CEO of Hansa Medical AB. Study results could potentially form the basis for filing a Biologics License Application, i.e. an application to the US Food and Drug Administration (FDA) for authorization to commercialize IdeS in the US. Hansa Medical is currently evaluating the possibility to add European sites to this now initiated study in order to support the regulatory process at the European Medicines Agency, EMA, for marketing authorization of IdeS in the European market. This study was cleared by the FDA in April 2016. More information about this trial in refractory highly sensitized patients is available at www.clinicaltrials.gov under the identifier NCT02790437. The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact person below on July 19, 2016 at 08.30 CET For further information, please contact: Hansa Medical AB Göran Arvidson, CEO Mobile: 46 70-633 30 42 E-mail: goran.arvidson@hansamedical.com www.hansamedical.com About refractory highly sensitized patients Approximately one third of the kidney patients that require dialysis are sensitized to human leukocyte antigens (HLA). The presence of antibodies that react with a potential donor organ is a significant barrier to transplantation due to the risk of acute antibody mediated rejection. Sensitized patients in general have an increased waiting time for transplantation. Depending on level of HLA-immunization, some sensitized patients can be transplanted with treatment procedures using plasmapheresis or intravenous gamma globulin at some specialized clinics. Refractory highly sensitized patients are highly sensitized patients that have either failed on previous attempts of desensitization or in whom effective desensitization using currently available methods is highly unlikely. About IdeS IdeS, a unique molecule with a novel mechanism, is an enzyme that specifically cleaves human IgG antibodies. During 2013, a Phase I clinical trial including 29 healthy subjects was conducted, demonstrating IdeS as efficacious and well tolerated with a favorable safety profile. During 2014, a Phase II study in 8 sensitized patients awaiting kidney transplantation was conducted. Data from the study show that IdeS is effective in reducing anti-HLA antibody levels in highly sensitized patients to levels acceptable for transplantation. The efficacy and safety of IdeS in transplantation are currently investigated in two on-going clinical trials in sensitized kidney patients in Sweden and in the U.S. In addition to transplantation, IdeS has potential applications in a variety of rare autoimmune diseases. IdeS is protected by several patents and results of studies with IdeS have been published in a number of peer reviewed scientific journals. About Hansa Medical AB Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq Stockholm.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 30

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Retainers Are the Unflashy Finish to Orthodontic Care

Updated Category News Views 93

A straight smile has an inconvenient habit of remembering where it came from. That is the plainspoken point in Dr. Michael McClain’s discussion of retainers after braces or Invisalign: the dramatic part of orthodontic treatment may be over when appliances come off, but the maintenance phase has barely started. It is not glamorous, and plenty of people probably wish it...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 74

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
PepsiCo Locks In Hyatt's 700-Property U.S. Supply Deal

Updated Category News Views 40

A hotel minibar is a lousy place to hunt for glamour, but it is a terrific place to spot durable distribution. PepsiCo has renewed its U.S. food and beverage relationship with Hyatt for 10 years, covering more than 700 properties. Nobody should pretend a hotel contract transforms a company with nearly $94 billion in 2025 revenue. Still, this is the sort of unflashy...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 25

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
TNBC Advocate Campaign Targets Gaps in Patient Clarity

Updated Category News Views 52

Triple-negative is a heavy phrase to hand somebody without a map. Tigerlily Foundation and the Breast Cancer Resource Center are trying to close that gap with a national education campaign scheduled to launch publicly on January 11, 2027. The plan is straightforward on paper: train and mobilize 100 patient advocates across the country to explain triple-negative breast...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 64

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 117

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 81

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading

Top 5 Most Recently Viewed Articles

Health Monitor Network Strengthens Leadership in Data Insights

Updated Category News Views 195

Strategic Appointment in Health Monitor Network Health Monitor Network, a renowned leader in point of care marketing, has taken a significant leap towards enriching its data analytics and research capabilities with the appointment of Lucia Burchell as Senior Vice President, Analytics, Research & Insights. Burchell's role is poised to empower clients by providing profound...

Continue Reading
Empowering Smallholders in Palm Oil for Sustainable Growth

Updated Category News Views 192

Empowering Smallholders in Palm Oil for Sustainable Growth From financing smallholders to regenerating ecosystems and innovating supply chains, the Roundtable on Sustainable Palm Oil (RSPO) has gathered global stakeholders to explore scalable solutions. This annual conference, an important event in the palm oil industry's agenda, aims to accelerate the industry's...

Continue Reading
t'order Welcomes New CTO to Drive Global Expansion Efforts

Updated Category News Views 169

t'order Inc. Appoints New Chief Technology Officer t'order Inc. has made a significant move by appointing Theo Eom as its Chief Technology Officer. With his extensive background in the tech industry, Theo is expected to lead the company in its ambitious plans for growth and innovation in the table-ordering service sector. The Technology Experience of Theo Eom Theo Eom...

Continue Reading
Manasquan Bank Introduces Home Loans for Local Heroes

Updated Category News Views 266

Supporting Our Local Heroes with New Home Lending Programs Manasquan Bank has proudly introduced innovative home lending products specifically designed for the heroes in our community. This initiative encompasses the dedication provided by educators, first responders, and military personnel. Aimed at making homeownership more achievable, these programs illustrate the...

Continue Reading
Netflix's Strategic Moves Drive Subscriber Gains Amid Prices Rise

Updated Category News Views 285

Netflix's Surging Subscriber Growth Through New Releases Netflix Inc. (NASDAQ: NFLX) has seen a notable uptick in its stock as it capitalizes on substantial gains from international markets and successful content releases. Major titles like Squid Game Season 3 and Stranger Things Season 5 have been pivotal in attracting new subscribers and enhancing user engagement....

Continue Reading